About
Apriligen develops autologous lentiviral gene therapies targeting rare monogenic pediatric diseases, initially focusing on RPS19 deficient Diamond Blackfan Anemia.
Explore Apriligen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.